Clinical trials: Schizo-Affective Disorder
- Condition Schizo-Affective Disorder
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Schizophrenia, Schizoaffective Disorder
Schizophrenic Patients in Integrated Care
The purpose of the study is to investigate the well-being of schizophrenic patients treated with quetiapine XR combined with participation in the integrated care program compared to a treatment with quetiapine XR alone over a…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- CARE II (NCT00681629)
- Testing
- Quetiapine XR, Integrated Care Program (ICP)
- Where
- 8 sites in Germany
- Volunteers
- 7 people
- Sponsor
- AstraZeneca
Schizophrenia, Schizoaffective Disorder
An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With Schizophrenia
The purpose of this study is to evaluate the long-term efficacy and safety of a long-acting injectable formulation of risperidone (an antipsychotic medication) and its influence on quality of life, in participants with…
- Trial name
- NCT00269919
- Testing
- Risperidone Long-Acting Injectable (RLAI)
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Janssen Korea, Ltd., Korea
Schizophrenia, Schizoaffective Disorder
Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia
Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is safe and tolerable long term among clinically stable patients.
- Trial name
- NCT00641745
- Testing
- Lurasidone HCl, Risperidone
- Where
- 73 sites in United States, Argentina and 6 more
- Volunteers
- 629 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia, Schizoaffective Disorder
Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia
The current study has been designed to address the significance of early onset of response prospectively in patients treated with an atypical antipsychotic.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00337662
- Testing
- olanzapine, risperidone
- Where
- 34 sites in United States, Argentina and 1 more
- Volunteers
- 628 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Psychotic Disorders
A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to investigate whether a long-acting injectable formulation of risperidone provides better effectiveness over 2 years, as measured by the time to relapse, compared with quetiapine tablets in a routine…
- Trial name
- NCT00216476
- Testing
- Aripiprazole, Risperidone Long Acting Injectable (LAI), Quetiapine
- Where
- 96 sites in Austria, Bulgaria and 22 more
- Volunteers
- 753 people
- Sponsor
- Janssen-Cilag International NV
Schizoaffective Disorder, Psychotic Disorder
Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.
The purpose of this study is to measure the effectiveness and assess the safety of two dosages of the antipsychotic paliperidone extended-release (ER) in patients who are experiencing an acute episode of schizoaffective disorder.
- Trial name
- NCT00397033
- Testing
- Paliperidone ER
- Volunteers
- 316 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Schizoaffective Disorder
A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder
Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia.
- Trial name
- Switch Ext (NCT01143090)
- Testing
- Lurasidone HCl
- Where
- 27 sites in United States
- Volunteers
- 149 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia, Schizoaffective Disorders
Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine
The goal of this study is to answer the following questions: Whether treatment with amantadine, metformin or zonisamide can prevent or reverse the weight gain that is associated with olanzapine Whether taking amantadine…
- Trial name
- NCT00401973
- Testing
- olanzapine, amantadine, metformin
- Where
- 15 sites in United States, Brazil and 5 more
- Volunteers
- 199 people
- Sponsor
- Eli Lilly and Company
Schizoaffective Disorder, Psychotic Disorder
Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.
The purpose of this study is to measure the effectiveness and assess the safety of different dosages (from 3 mg/day to 12 mg/day) of the antipsychotic paliperidone extended-release (ER) in patients who are experiencing an acute…
- Trial name
- NCT00412373
- Testing
- Paliperidone ER
- Where
- 44 sites in United States, India and 4 more
- Volunteers
- 307 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Schizoaffective Disorder
A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis
The purpose of this study is to evaluate the effectiveness, safety and tolerability of risperidone long-acting injection (LAI) versus oral antipsychotics in participants with recent onset psychosis (abnormal thinking and/or…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorders
- Trial name
- NCT00246259
- Testing
- Risperidone long-acting injection (LAI), Oral Antipsychotic
- Where
- 11 sites in Canada
- Volunteers
- 77 people
- Sponsor
- Janssen-Ortho Inc., Canada
Schizophrenia, Schizoaffective Disorder
A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
This study investigates the effects of RO6889450 on the negative symptoms associated with schizophrenia and schizoaffective disorder.
- Trial name
- NCT03669640
- Testing
- RO6889450
- Where
- 45 sites in United States, Japan and 2 more
- Volunteers
- 131 people
- Sponsor
- Hoffmann-La Roche
Agitation, Schizophrenia
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia
This is a definitive study to support the safety and efficacy evaluation of BXCL501 for the acute treatment of agitation in schizophrenia.
- Conditions
- Agitation, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder
- Trial name
- SERENITY I (NCT04268303)
- Testing
- Sublingual film containing dexmedetomidine (BXCL501)
- Where
- 15 sites in United States
- Volunteers
- 380 people
- Sponsor
- BioXcel Therapeutics Inc
Schizophrenic Disorders
Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose
This pilot trial in Finland is designed to evaluate in a randomized fashion change of agitation in acute schizophrenic patients (Schizophrenia or Schizoaffective psychosis or Schizophreniformic psychosis)Diagnostic and…
- Trial name
- NCT00660595
- Testing
- Quetiapine, Risperidone
- Where
- 4 sites in Finland
- Volunteers
- 29 people
- Sponsor
- AstraZeneca
Smoking Cessation
Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder
Study will determine whether patients with schizophrenia or schizoaffective disorder can be helped to quit smoking safely while using varenicline and receiving smoking cessation counseling.
- Trial name
- NCT00644969
- Testing
- varenicline (CP-526,555)
- Where
- 14 sites in United States, Canada
- Volunteers
- 128 people
- Sponsor
- Pfizer
Schizoaffective Disorder
A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder
This study will evaluate the efficacy of paliperidone palmitate compared with placebo in the delay of relapse of the symptoms of schizoaffective disorder.
- Trial name
- NCT01193153
- Testing
- paliperidone palmitate
- Where
- 80 sites in United States, Bulgaria and 6 more
- Volunteers
- 667 people
- Sponsor
- Janssen Scientific Affairs, LLC
Schizophrenia, Schizoaffective Disorder
A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents
Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia.
- Trial name
- SWITCHCore (NCT01143077)
- Testing
- Lurasidone HCl
- Where
- 27 sites in United States
- Volunteers
- 244 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia, Schizoaffective Disorder
Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome
The purpose of this study was to determine whether patients with schizophrenia, schizoaffective disorder, or bipolar I disorder who also have metabolic syndrome have a larger decrease in fasting non-high density lipoprotein…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar I Disorder, Metabolic Syndrome
- Trial name
- NCT00857818
- Testing
- Aripiprazole, Oanzapine, risperidone, or quetiapine
- Where
- 14 sites in Canada
- Volunteers
- 64 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia
This study will evaluate the effectiveness of valbenazine on patient- and clinician-reported outcomes assessing health-related quality of life, functioning, and treatment effect in participants with tardive dyskinesia (TD) who…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT05859698
- Testing
- Valbenazine
- Where
- 18 sites in United States
- Volunteers
- 59 people
- Sponsor
- Neurocrine Biosciences
Schizophrenia, Schizoaffective Disorder
Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to establish pharmacodynamics (PD), pharmacokinetics (PK), and adverse event (AE) profile of OPC-34712 administered to schizophrenic/schizoaffective subjects.
- Trial name
- NCT01423916
- Testing
- OPC-34712 (4mg), Moxifloxacin, OPC-34712 (12mg)
- Where
- 8 sites in United States
- Volunteers
- 218 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
This study will investigate the efficacy and safety of RO6889450 as monotherapy in participants experiencing an acute exacerbation of symptoms of schizophrenia or schizoaffective disorder.
- Trial name
- NCT04512066
- Testing
- RO6889450, Risperidone
- Where
- 40 sites in United States, Japan and 2 more
- Volunteers
- 287 people
- Sponsor
- Hoffmann-La Roche